← back to search

George Boon‐Bee Goh

Inova Health System · US
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Hepatocellular Carcinoma Treatment and Prognosis, and Diabetes, Cardiovascular Risks, and Lipoproteins.
h-index
34
citations
4,911
works
155
NIH funding
primary concept
Medicine
email

Recent publications

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Hepatology International 2025cited by 110position: middledoi
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease
Journal of Hepatology 2025cited by 33position: middledoi
Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
Gut and Liver 2025cited by 31position: lastdoi
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
Journal of Hepatology 2025cited by 29position: middledoi
From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective
Gastroenterology 2025cited by 20position: middledoi
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
Gut 2025cited by 18position: middledoi
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
Clinical Gastroenterology and Hepatology 2025cited by 16position: middledoi
Targeting Treg–fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma
Gut 2025cited by 12position: middledoi
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD
Clinical Gastroenterology and Hepatology 2025cited by 10position: middledoi
Association between longitudinal weight change and clinical outcome in individuals with MASLD
Hepatology 2025cited by 8position: middledoi
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
Hepatology 2025cited by 8position: middledoi
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Hepatology 2025cited by 6position: middledoi
Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study
Hepatology 2025cited by 6position: middledoi
IDDF2025-ABS-0058 Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in metabolic dysfunction-associated steatotic liver disease
2025cited by 0position: middledoi
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
JAMA 2024cited by 192position: middledoi
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Gut 2024cited by 77position: middledoi
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Hepatology International 2024cited by 31position: middledoi
Gestational diabetes mellitus and development of intergenerational non-alcoholic fatty liver disease (NAFLD) after delivery: a systematic review and meta-analysis
EClinicalMedicine 2024cited by 21position: middledoi
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study
Clinical Gastroenterology and Hepatology 2024cited by 15position: middledoi
Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis
Hepatology International 2024cited by 13position: middledoi
Single-cell and spatial atlas of steatotic liver disease-related hepatocellular carcinoma
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 2position: middledoi
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Hepatology International 2023cited by 180position: middledoi
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Nature Medicine 2023cited by 156position: middledoi
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Clinical and Molecular Hepatology 2023cited by 64position: middledoi
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Hepatology 2023cited by 63position: middledoi
Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition
Journal of Clinical Investigation 2023cited by 27position: middledoi
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
Journal of Hepatology 2022cited by 152position: middledoi
Advancing the global public health agenda for NAFLD: a consensus statement
Nature Reviews Gastroenterology & Hepatology 2021cited by 722position: middledoi
Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study
Metabolism 2021cited by 58position: middledoi
Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma
Scientific Reports 2019cited by 146position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wei Qiang Leow · Singapore General Hospital5 papers (2019–2024)Vincent Wai‐Sun Wong · Second Affiliated Hospital of Xi'an Jiaotong University4 papers (2016–2023)Yock Young Dan · National University of Singapore3 papers (2019–2024) · 3 papers (2016–2019)Khek Yu Ho · National University of Singapore2 papers (2019–2021)Kento Imajo · Yokohama City University2 papers (2019–2021)Hwai‐I Yang · Brown University2 papers (2016–2023) · 2 papers (2019–2021)Brian K. P. Goh · Singapore General Hospital2 papers (2019–2024) · 2 papers (2019–2021)Dina Tiniakos · National and Kapodistrian University of Athens2 papers (2019–2022)Quentin M. Anstee · Newcastle upon Tyne Hospital2 papers (2019–2022)Pierce K. H. Chow · SingHealth2 papers (2019–2024) · 2 papers (2019–2019)Khean‐Lee Goh · University of Iowa2 papers (2019–2021)Wah‐Kheong Chan · University of Malaya2 papers (2019–2021)Ajay Duseja · All India Institute of Medical Sciences Bhubaneswar2 papers (2019–2021)Stephen A. Harrison · Oxford Centre for Diabetes, Endocrinology and Metabolism2 papers (2019–2022)Aileen Wee · National University of Singapore2 papers (2019–2022) · 2 papers (2019–2021)